Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02881931 · ClinicalTrials.gov registry record
FuRST 2.0 Cognitive Pre-Testing
A clinical trial of Huntington's Disease, sponsored by CHDI Foundation.
- Completed
- Registry status
- 75
- Enrollment target
- 4
- Study locations
NCT02881931: Completed study of Huntington's Disease, sponsored by CHDI Foundation.
NCT02881931 is a study of Huntington's Disease that has completed, run by CHDI Foundation. The registered enrollment target is 75 participants, below the 4,784-participant average among 8 other Huntington's Disease trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02881931, a study of Huntington's Disease, has completed, sponsored by CHDI Foundation.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
- 4
- Study locations
Study Summary
The FuRST 2.0 scale is being developed as a Patient Reported Outcome (PRO) with information coming directly from the Huntington's Disease Gene Expansion Carrier (HDGEC) and companion through self-report. The purpose of this study is to identify real or potential comprehension or usage problems with questionnaire items or response options. Through a process of structured cognitive de-briefing with HDGEC participants and companions, independently, followed by qualitative analysis, the final phrasing of the individual items and response options for the scale will be generated. Depending on the results of the first round of cognitive pre-testing, additional rounds of cognitive pre-testing may be required.
Primary Outcome
The primary assessment will use qualitative analysis of the cognitive interview to determine the usability of the FuRST 2.0 scale in the HD population.
Conditions Studied
Interventions
- BEHAVIORAL FuRST 2.0
Study Locations (4)
Colorado
- Rocky Mountain Movement Disorders Center, P.C. - Englewood
Kansas
- Hereditary Neurology Disease Centre, Inc. - Wichita
New York
- Columbia University - New York
Ontario
- CENTRE FOR MOVEMENT DISORDERS (Neuropharm Consulting) - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2017-07-28 |
What the finished NCT02881931 record still lists
NCT02881931 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 4,784-participant average among 8 other Huntington's Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 1 intervention - of which FuRST 2.0 is the first listed.
NCT02881931 reports a single indexed study location in Colorado, Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT02881931 about?
NCT02881931 is a clinical study titled "FuRST 2.0 Cognitive Pre-Testing". The FuRST 2.0 scale is being developed as a Patient Reported Outcome (PRO) with information coming directly from the Huntington's Disease Gene Expansion Carrier (HDGEC) and companion through self-report. The purpose of this study is to identify real or potential comprehension or usage problems with ...
What is the current status of trial NCT02881931?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2017-02-28. Estimated completion is 2017-07-28.
What conditions does trial NCT02881931 study?
This clinical trial studies the following conditions: Huntington's Disease.
What interventions are being tested in trial NCT02881931?
The interventions under investigation include: FuRST 2.0 (BEHAVIORAL).
Who is sponsoring clinical trial NCT02881931?
This trial is sponsored by CHDI Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02881931 being conducted?
This trial has 4 study locations across Colorado, Kansas, New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02881931's enrollment target sits among peer trials
75 5th of 8 higher than 4 of 8 other Huntington's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
RECRUITING
-
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
RECRUITING
-
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
RECRUITING
-
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
COMPLETED · Phase 1
-
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI